Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study

Lene Boesby, Thomas Elung-Jensen, Tobias Wirenfeldt Klausen, Svend Strandgaard, Anne-Lise Kamper, Lene Boesby, Thomas Elung-Jensen, Tobias Wirenfeldt Klausen, Svend Strandgaard, Anne-Lise Kamper

Abstract

Background: Reduction of proteinuria and blood pressure (BP) with blockers of the renin-angiotensin system (RAS) impairs the progression of chronic kidney disease (CKD). The aldosterone antagonist spironolactone has an antiproteinuric effect, but its use is limited by side effects. The present study evaluated the short-term antiproteinuric effect and safety of the selective aldosterone antagonist eplerenone in non-diabetic CKD.

Study design: Open randomized cross-over trial.

Setting and participants: Forty patients with non-diabetic CKD and urinary albumin excretion greater than 300 mg/24 hours.

Intervention: Eight weeks of once-daily administration of add-on 25-50 mg eplerenone to stable standard antihypertensive treatment including RAS-blockade.

Outcomes & measurements: 24 hour urinary albumin excretion, BP, p-potassium, and creatinine clearance.

Results: The mean urinary albumin excretion was 22% [CI: 14,28], P < 0.001, lower during treatment with eplerenone. Mean systolic BP was 4 mmHg [CI: 2,6], P = 0.002, diastolic BP was 2 mmHg [CI: 0,4], P = 0.02, creatinine clearance was 5% [CI: 2,8], P = 0.005, lower during eplerenone treatment. After correction for BP and creatinine clearance differences between the study periods, the mean urinary albumin excretion was 14% [CI: 4,24], P = 0.008 lower during treatment. Mean p-potassium was 0.1 mEq/L [CI: 0.1,0.2] higher during eplerenone treatment, P<0.001. Eplerenone was thus well tolerated and no patients were withdrawn due to hyperkalaemia.

Limitations: Open label, no wash-out period and a moderate sample size.

Conclusions: In non-diabetic CKD patients, the addition of eplerenone to standard antihypertensive treatment including RAS-blockade caused a moderate BP independent fall in albuminuria, a minor fall in creatinine clearance and a 0.1 mEq/L increase in p-potassium.

Trial registration: Clinicaltrials.gov NCT00430924.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Urinary albumin excretion.
Figure 1. Urinary albumin excretion.
Figure 1A illustrates albumin excretion during 8 weeks of add-on eplerenone as compared with control. Figure 1B illustrates the difference in urinary albumin excretion between treatment with eplerenone and control. Data are presented as mean values with 95% CI of the mean values. * P

Figure 2. P-potassium during 8 weeks of…

Figure 2. P-potassium during 8 weeks of add-on eplerenone as compared with control.

Data are…

Figure 2. P-potassium during 8 weeks of add-on eplerenone as compared with control.
Data are presented as mean values with 95% CI of the mean values.
Figure 2. P-potassium during 8 weeks of…
Figure 2. P-potassium during 8 weeks of add-on eplerenone as compared with control.
Data are presented as mean values with 95% CI of the mean values.

References

    1. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309–2320.
    1. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–1140.
    1. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–762.
    1. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). Kidney Int. 1998;53:1209–1216.
    1. Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 2003;63:2254–2261.
    1. Kamper AL, Strandgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens. 1992;5:423–430.
    1. Kanno Y, Takenaka T, Nakamura T, Suzuki H. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol. 2006;1:730–737.
    1. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis. 2001;37:677–688.
    1. Hostetter TH, Rosenberg ME, Ibrahim HN, Juknevicius I. Aldosterone in progressive renal disease. Semin Nephrol. 2001;21:573–579.
    1. Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol. 2008;12:233–242.
    1. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116–2123.
    1. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006;1:256–262.
    1. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens. 2005;18:44–49.
    1. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829–2836.
    1. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536–542.
    1. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940–951.
    1. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003;41:1021–1026.
    1. Cravedi P, Brusegan V, Ruggenenti P, Campbell R, Remuzzi G. Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work? Pharmaceuticals. 2010;3:1–9.
    1. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641–2650.
    1. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008;31:59–67.
    1. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008;52:486–493.
    1. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005;46:45–51.
    1. Uhrenholt TR, Schjerning J, Hansen PB, Norregaard R, Jensen BL, et al. Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res. 2003;93:1258–1266.
    1. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, et al. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006;47:1084–1093.
    1. Rudolph AE, Rocha R, McMahon EG. Aldosterone target organ protection by eplerenone. Mol Cell Endocrinol. 2004;217:229–238.
    1. Arima S. Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculation. J Steroid Biochem Mol Biol. 2006;102:170–174.
    1. Schmidt BM. Rapid non-genomic effects of aldosterone on the renal vasculature. Steroids. 2008;73:961–965.
    1. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, et al. Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology. 2005;146:973–980.
    1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.
    1. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15:79–87.
    1. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118:1643–1650.
    1. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–551.
    1. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31:153–158.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться